Anzeige
Mehr »
Login
Freitag, 15.01.2021 Börsentäglich über 12.000 News von 656 internationalen Medien
Das ist der Durchbruch! Die >Billionen News< in der Covid-19-Schlacht!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRW ISIN: SE0015244520 Ticker-Symbol: BIX0 
Stuttgart
15.01.21
16:59 Uhr
5,210 Euro
+0,025
+0,48 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOINVENT INTERNATIONAL AB Chart 1 Jahr
5-Tage-Chart
BIOINVENT INTERNATIONAL AB 5-Tage-Chart

Aktuelle News zur BIOINVENT Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BIOINVENT Aktie jetzt für 0€ handeln
MoBioInvent streamlines agreement on anti-FcyRllB antibody, BI-1206, ahead of Phase I/II data327LUND, Sweden, Jan. 11, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces it has restructured a clinical development agreement with...
► Artikel lesen
23.12.20BioInvent secures $3M on selection of antibodies under collaboration pact with Pfizer8
23.12.20BioInvent receives $3 million payment related to selection of antibodies under collaboration with Pfizer Inc.315LUND, Sweden, Dec. 23, 2020 /PRNewswire/ -- BioInvent International AB (OMXS: BINV ), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...
► Artikel lesen
21.12.20BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors223LUND, Sweden and STRASBOURG, France, Dec. 21, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel...
► Artikel lesen
21.12.20Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors191Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International...
► Artikel lesen
14.12.20XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 14.12.20201.126The following instruments on XETRA do have their first trading 14.12.2020 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 14.12.2020 Aktien 1 KYG5074A1004 JD Health International...
► Artikel lesen
11.12.20XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 11.12.20201.177The following instruments on Boerse Frankfurt do have their last trading day on 11.12.2020 Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 11.12.2020 ISIN Name DE000A1ZLZC3 WITR...
► Artikel lesen
11.12.20XFRA ISIN CHANGE3.072Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen IT0005108763 Banca Carige S.p.A. 11.12.2020 IT0005428195 Banca Carige S.p.A. 14.12.2020 Tausch 1000:1 GB00BFXZC448 Aston...
► Artikel lesen
11.12.20XFRA CAPITAL ADJUSTMENT INFORMATION - 11.12.20201.130CAPITAL ADJUSTMENT INFORMATION - 14.12.2020:Das Instrument TY3S DE000A1ZLZC3 WITR MU.AS.I.3S.TRES14/62 ETN wird cum Kapitalmassnahme gehandelt am 11.12.2020 und ex Kapitalmassnahme am 14.12.2020 The...
► Artikel lesen
09.12.20Nomination Committee appointed for BioInvent International's Annual General Meeting 2021317LUND, Sweden, Dec. 9, 2020 /PRNewswire/ -- The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent) Annual General Meeting in 2021 have now been appointed. The...
► Artikel lesen
08.12.20Nasdaq Stockholm AB: Reverse Split and Change of ISIN for BioInvent International AB (190/20)219Referring to the bulletin from BioInvent International AB's extraordinary general meeting, held on November 27, 2020, the company will carry out a reverse stock split in relations 1:25. The share will...
► Artikel lesen
07.12.20Record date for reverse share split in BioInvent International determined303LUND, Sweden , Dec. 7, 2020 /PRNewswire/ -- At the Extraordinary General Meeting of BioInvent International AB (publ) ("BioInvent") on 27 November 2020, a reverse share split was resolved...
► Artikel lesen
27.11.20Resolutions at the Extraordinary General Meeting in BioInvent on November 27, 2020310LUND, Sweden, Nov. 27, 2020 /PRNewswire/ -- BioInvent International AB's (publ) ("BioInvent") (OMXS: BINV) Extraordinary General Meeting (the "EGM") today resolved to approve the Board of...
► Artikel lesen
27.11.20BioInvent strengthens Investor Relations299LUND, Sweden, Nov. 27, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...
► Artikel lesen
26.11.20BioInvent inks antibody manufacturing agreement with Cantargia-
26.11.20BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10359LUND, Sweden, Nov. 26, 2020 /PRNewswire/ -- Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia's...
► Artikel lesen
26.11.20BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10364LUND, Sweden , Nov. 26, 2020 /PRNewswire/ -- Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of...
► Artikel lesen
26.11.20CANTARGIA AB: BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN105
09.11.20Transgene And BioInvent Present Data on Next Generation Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting207Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International...
► Artikel lesen
09.11.20BioInvent and Transgene present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting211LUND, Sweden and STRASBOURG, France, Nov. 9, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel...
► Artikel lesen
Seite:  Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5
sist1